Record-3: Phase III randomized trial comparing seqential first-line everolimus (EVE) and second-line sunitinib (SUN) verusus first-line SUN and second-line EVE in patients with metastatic renall cell carcinoma (mRCC) - Motzer, R J; Barrios, C H; Kim, T M (J Clin Oncol, 2013)
Abstr. 4504